OncoSil secures TGA approval for pancreatic cancer device
Approval of device in Australia for treating locally advanced pancreatic cancer alongside gemcitabine-based chemotherapy
Approval of device in Australia for treating locally advanced pancreatic cancer alongside gemcitabine-based chemotherapy
The Ma’anshan site approval covers pastilles, oral liquids, and powders
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years
Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management
Tiotropium (as bromide monohydrate) 18 micrograms powder for inhalation in capsule
The company plans to expand its portfolio in regulated markets aggressively
Clearing 19 biologics for Europe market
Subscribe To Our Newsletter & Stay Updated